Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 234

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 234
---
 Exchange Act. Our Compensation Committee’s main function is to oversee our compensation structure, policies and programs and to review the processes and procedures for the consideration and determination of director and executive compensation. The Compensation Committee’s responsibilities include, among other things:

| ● | recommending to the board of directors goals and objectives,       
 non-equity compensation, and equity grants of all senior officers; |

| ● | recommending to the board of directors goals and objectives,                
 non-equity compensation, and equity grants for the Chief Executive Officer; |

| ● | recommending to the board of directors non-equity compensation 
 and equity grants for the directors;                           |

| ● | reviewing and discussing with the board of directors corporate     
 succession plans for the Chief Executive Officer and key officers; |

| ● | reviewing and discussing with management its talent development 
 and related initiatives;                                        |

| ● | assisting the board of directors with its oversight of our                                                                                     
 strategies, programs, and initiatives related to employee health, safety, and well-being, engagement, pay equity, and diversity and inclusion; |

| ● | selecting independent compensation consultants and assessing                                                
 whether there are any conflicts of interest with any of the Compensation Committee’s compensation advisors; |

| ● | reviewing and recommending to the board of directors employment                                                                       
 agreements, severance arrangements and change-of-control agreements or provisions for executive officers and other senior management, 
 as appropriate; and                                                                                                                   |

| ● | reviewing the policies relating to compensation and benefits 
 of employees.                                                |

Nominating and Corporate Governance Committee The members of our nominating and corporate governance committee are Dr. Rolfe, Ms. LaPorte and Mr. Byrnes. Dr. Rolfe serves as the chairperson of the committee. Our board of directors has determined that each of Dr. Rolfe, Ms. LaPorte and Mr. Byrnes is independent under the applicable Nasdaq listing standards. 134 The nominating and corporate governance committee’s main function is to consider candidates for board membership and oversee our corporate governance policies, reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors. The nominating and corporate governance committee’s responsibilities include, among other things:

| ● | recommending to the board of directors for its approval criteria 
 for board of directors and committee membership;                 |

| ● | establishing a process for identifying and evaluating board             
 of director candidates, including nominees recommended by stockholders; |

| ● | identifying individuals qualified to become members of the 
 board of directors;